Terms and conditions
Acceptable use policy
Unit 1 City Business Centre,
6 Brighton Road, Horsham,
West Sussex, RH13 5BB
Telephone: 01403 264898
VAT number: 333 2797 52
£80 + VAT
Non-Member price: £95 + VAT
Book your place online now
This two-hour workshop will consider whether there is any way pharmaceutical companies can work effectively in social media given the restrictions of compliance and the chaos of digital interactions in the wild.
Four industry speakers will give their perspective with ample opportunity for debate and audience participation. The meeting will conclude with an interactive panel discussion with audience members.
Reception with teas & coffees
Welcome and introduction
Chair: Dr Nick BroughtonNick will set out the aims of the event and introduce the three other speakers.
The social media conundrum
Dr Nick Broughton, Compliance Partner, Makara Health Read Bio
Nick will set out what he sees as the main issues for pharma in social media reflecting on good and bad ways of working. He will propose that the pharma industry’s struggles with social media have simply highlighted deeper deficiencies in the commercial-compliance operating paradigm. Nick will set the context for the other presentations that will offer solutions to the problems raised.
The business value of social media – context, application and examples
Alex Butler, Co-founder Foundry3 Read Bio
Given that medicines cannot be promoted to the public and that the penalties for doing so make everyone risk averse, what is the point of pharmaceutical companies attempting to engage in social media?
Felix and Alex will consider what social media is and where it fits in the wider context of rapid technological changes in healthcare. They will then focus on the business value of social media in various aspects of pharma activity and present specific examples of best practice and value. They will emphasise the importance of communicating value to internal stakeholders.
Making things happen
Dr Mark Toms, Chief Scientific Officer, Novartis UK Read Bio
Mark will consider the ethical and compliance challenges of working as a large pharmaceutical company in social media, shedding light on why there is nervousness amongst those whose signatures are required to make things happen.
Mark will explore the compliance obligations of pharmaceutical companies and propose that they are not as restrictive as they are frequently interpreted to be. He will illustrate his argument with best practice examples and challenge commercial and compliance functions to make things happen.
The speakers will participate in a panel discussion, answering questions submitted by the audience who will be encouraged to actively participate and exchange views.
Summary and conclusions
Chair: Dr Nick Broughton
Nick will summarise the learnings from the event and the outcomes of the panel discussion.